TB-500 Guide & Protocols

Search TB-500 dosing and you'll find nearly the same answer everywhere: 2 to 2.5 milligrams twice a week for four to six weeks, then a weekly maintenance amount. It's repeated so consistently it reads like settled practice, and yet nobody carrying it cites anything for it. Below is the pattern most commonly referenced, where it most likely actually comes from, how it's cycled and stacked, and how it compares to BPC-157.

Vial size isn't part of what follows, since the amount of bacteriostatic water you add sets your concentration either way. Our reconstitution calculator handles that math for whatever vial and target dose you're working with.

What it is

TB-500 is a synthetic peptide matching residues 17 through 23 of thymosin beta-4, a naturally occurring protein involved in cell movement and repair, built through standard peptide synthesis rather than drawn from a biological source. The commercial product is a short acetylated fragment, and it's sometimes used interchangeably with thymosin beta-4 in casual conversation, even though the two are structurally distinct, one being the full protein and the other a small piece of it. It's sold as a research chemical, not an FDA-approved drug or supplement, and it's frequently discussed alongside BPC-157.

What people use it for

TB-500 shows up mainly in tissue repair and recovery conversations, tendons, muscle, and connective tissue, through its proposed role in cell migration. A cardiac-repair angle comes up in early research, though that work is still in animal and cell models. A longevity and cellular-aging framing shows up too, tied to the same repair signaling. One caveat worth being upfront about: the human clinical work behind this compound class, mainly eye-drop research for a corneal nerve condition, belongs to the parent protein, thymosin beta-4, given a completely different way. It isn't evidence for TB-500 itself.

Formulations

TB-500 ships as a lyophilized (freeze-dried) powder that needs reconstitution before use. Vendors most commonly sell 5 mg and 10 mg vials. There's no oral or nasal commercial formulation, so subcutaneous injection of the reconstituted solution is the route people run.

Dosing protocols

There's no single settled dose for TB-500. What circulates is a handful of patterns, and the most repeated one has essentially no traceable origin, so here's each pattern with where it actually comes from.

See the TB-500 research notes for more background before reading the dosing itself.

Most commonly referenced pattern, loading then maintenance

2 to 2.5 mg twice weekly for 4 to 6 weeks, then 2 to 2.5 mg weekly or every other week. This is the single most repeated peptide protocol in this whole space, and not one source carrying it cites anything for it. One site listing it references eleven sources elsewhere on the page, none of which actually support this figure.

A wider-range variant

2 to 5 mg twice weekly for 4 to 6 weeks within an 8 to 12 week cycle, then 2 mg weekly, with 4 weeks off between cycles. Commonly found in vendor education, with the same absent provenance as the pattern above.

A variant with no loading phase

0.5 to 2.5 mg, two or three times weekly. Commonly attributed to Ben Greenfield, a health author and podcaster, who states directly that there are very few real guidelines behind TB-500 dosing.

A daily variant

2 mg daily for the first 15 days, then 1 mg daily. Found in vendor-adjacent education that acknowledges its own protocol hasn't been validated anywhere, a third distinct frequency from the patterns above.

The loading-then-maintenance shape most commonly referenced has a real published match, just not in people: an equine product insert describes one 10 milligram vial weekly for six weeks, then one vial monthly, for horses. TB-500 circulated in veterinary and racing use before it reached human forums, and that same architecture, weeks of loading followed by a long maintenance gap, at a scale suited to an animal several times the size of a person, carries the fingerprints of that origin more than of anything published in people.

It's also worth naming plainly: any human dosing data that exists for this compound class was measured for the full-length parent protein, given directly into the bloodstream, not for the short fragment sold as TB-500, injected under the skin. Those are different inputs by a different route, and the amounts don't translate across.

One more thing worth naming: the patterns above are nearly always a flat 2 to 2.5 milligrams, whether the person weighs 110 pounds or 240, and none of them adjust for size. That doesn't make the flat amount wrong for a given person, it makes it unexamined for them, which is worth knowing.

Cycling guidelines

A loading phase followed by a lighter maintenance stretch is the shape nearly every version of this protocol shares, commonly run for 2 to 6 months before a break, though the specific timing varies by which pattern above someone is following. We couldn't find a source establishing where the loading-to-maintenance ratio came from beyond the equine parallel noted above.

Signs a course is commonly stopped early:

• Persistent injection-site reaction beyond mild, brief redness
• Any new symptom you can't otherwise explain
• No noticeable change at all well past the point earlier reports describe one showing up, though this is a soft signal at best

Stacking

Most popular stack: TB-500 and BPC-157, sometimes called the Wolverine blend.

Rationale: the two are studied through different mechanisms, broader cell-migration signaling for TB-500, gut and local tissue repair for BPC-157, and they're commonly discussed as complementary rather than redundant.

Protocol as run: both peptides on their own schedules from above, run over the same general weeks rather than on a single matched timetable.

Why it's paired: the two get marketed together constantly, largely because they answer to the same recovery-and-repair audience, not because there's a documented trial behind the combination.

Lighter stacks: GHK-Cu shows up alongside TB-500 in skin and collagen-focused stacks, addressing repair from a different angle. This is rationale plus a loosely matched schedule, not a protocol with dedicated combination data.

Combinations to approach carefully: running TB-500 alongside several other repair-focused peptides at once makes it harder to know which one is behind any change you notice, and we found no source addressing what a three- or four-peptide repair stack does as a combination rather than as separate parts.

Expected results timeline

Early days: mostly an adjustment period for the injection routine itself. Anything noticed in the first several days is more likely the routine or placebo than the compound doing its work.

During a loading phase: this is where most self-reported changes cluster, subjective recovery from soft-tissue strain or general training load, none of it measured against a control group.

Cumulative, across repeated cycles: this is the piece with the least real-world evidence behind it. The underlying data is overwhelmingly animal and cell work, not people, so a cumulative human effect is more assumption than finding.

What to expect realistically: a research base that's mostly preclinical, with the one meaningfully human-tested application belonging to a different molecule given a different way. Mild, self-reported improvements in recovery are the most commonly described signal. A measurable change without some way of tracking it isn't a reasonable expectation.

Administration technique

1. The lyophilized powder is reconstituted with bacteriostatic water, at a concentration set by the reconstitution calculator for the target dose.
2. The solution is swirled gently to dissolve rather than shaken, since agitation can degrade the peptide.
3. The calculated volume is drawn into an insulin syringe.
4. A subcutaneous site is chosen, commonly the abdomen or near the area of concern, with sites rotated across the course.
5. The skin is pinched and the injection given at roughly a 45-degree angle, held for a few seconds before withdrawal.
6. Each injection is commonly logged by date, amount, and site, so a multi-week loading phase doesn't rely on memory partway through.

Side effects and safety

Common: mild redness or irritation at the injection site.

Less common: mild fatigue reported during a loading phase.

What we don't know: there's no completed large-scale human safety study for TB-500 specifically. The veterinary and racing use noted above has its own separate track record that doesn't transfer directly to human use, and the parent molecule's human eye-drop research doesn't stand in for whole-body injection either.

Contraindications: pregnancy, breastfeeding, and use in minors all have no data behind them and should be avoided.

Drug interactions: none have been characterized. That's an absence of data, not evidence of safety.

TB-500 vs. BPC-157

If you're weighing TB-500 against something else, BPC-157 is the compound people actually cross-shop it against, since the two are marketed together constantly under the Wolverine name.

Choose TB-500 if: broader tissue repair is the focus and a digestive angle isn't part of what you're after.

Choose BPC-157 if: gut comfort matters too, or you want the option of an oral form alongside an injected one.

Stacking the two: this is the single most common peptide combination in this space, run on separate schedules rather than one matched protocol. See the full BPC-157 vs. TB-500 comparison for a deeper side-by-side, and the BPC-157 research notes for pricing and vendor info.

Storage and handling

Lyophilized powder: stable at room temperature or refrigerated, commonly described as good for 24 months or longer. Lot-specific stability should come from the vendor's certificate of analysis, not a general rule.

Reconstituted solution: refrigerate at 2 to 8°C, and plan to use it within about 4 weeks.

The wider-range variant above, an 8 to 12 week cycle with 4 to 6 weeks of loading followed by a lighter maintenance stretch, runs well past this 4-week window on its own. A cycle that length means reconstituting a fresh vial partway through, not stretching one reconstituted vial across the whole cycle.

Signs of degradation:

• Cloudiness or visible particles in a solution that was previously clear
• Discoloration of the powder or reconstituted liquid
• A cycle that produces none of the previously noticed subjective effects, though this is a soft signal at best

FAQ

Where does the loading-then-maintenance pattern actually come from? Not from anything published in people. The closest documented match is a published equine product instruction, scaled to a much larger body, which is why the shape carries the fingerprints of veterinary and racing use.

Is there real human dosing data for TB-500? Not for TB-500 itself. The human-tested application in this compound class belongs to the full-length parent protein, given a different way.

How long is a typical cycle? Most commonly 4 to 6 weeks of loading within a broader 2 to 6 month stretch, followed by a break, though the exact numbers vary by which pattern you're reading.

Is it safe to combine with BPC-157? No dedicated combination study exists. It's the most common pairing in this space, run on separate schedules rather than a single protocol.

Does body weight matter for dosing? The popular figures are a flat amount that doesn't adjust for size, which is worth knowing if you're meaningfully lighter or heavier than an average frame.

Is there human safety data? Not specific to TB-500. What exists either belongs to the parent molecule given differently, or to veterinary use that doesn't transfer directly.

How is it stored? Room temperature or refrigerated as a powder, refrigerated and used within about 4 weeks once reconstituted.

What's the difference between a 5 mg and 10 mg vial? Only the concentration and how many vials your cycle total requires; the reconstitution calculator handles the arithmetic either way.

Bottom line

Key dosing takeaways:

• 2 to 2.5 mg twice weekly for 4 to 6 weeks, then a weekly maintenance amount, is the pattern most commonly referenced, though it has no traceable source in anything published in people
• The closest documented match to that shape is a published equine product instruction, which is worth knowing before treating the human version as settled practice
• The human evidence that does exist for this compound class belongs to a different molecule, given a different way, and doesn't transfer directly

Best practices:

• Comparing vendors by cycle total in milligrams, not by vial count, is where the real price differences show up
• Logging each injection keeps a multi-week loading phase from relying on memory
• A break between cycles is standard across every version of this protocol, even though the specific timing has no traceable source

Works best for people who:

• Want broader tissue-repair support without needing a digestive angle addressed at the same time
• Are comfortable running a widely used protocol whose popular shape traces to veterinary literature rather than human evidence
• Are prepared to scale expectations to a mostly-preclinical evidence base